Atypical cell cycle regulation promotes mammary stem cell expansion during mammary development and tumourigenesis.

IF 7.4 1区 医学 Q1 Medicine Breast Cancer Research Pub Date : 2024-06-28 DOI:10.1186/s13058-024-01862-1
Bre-Anne Fifield, John Vusich, Erika Haberfellner, Eran R Andrechek, Lisa A Porter
{"title":"Atypical cell cycle regulation promotes mammary stem cell expansion during mammary development and tumourigenesis.","authors":"Bre-Anne Fifield, John Vusich, Erika Haberfellner, Eran R Andrechek, Lisa A Porter","doi":"10.1186/s13058-024-01862-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The cell cycle of mammary stem cells must be tightly regulated to ensure normal homeostasis of the mammary gland to prevent abnormal proliferation and susceptibility to tumorigenesis. The atypical cell cycle regulator, Spy1 can override cell cycle checkpoints, including those activated by the tumour suppressor p53 which mediates mammary stem cell homeostasis. Spy1 has also been shown to promote expansion of select stem cell populations in other developmental systems. Spy1 protein is elevated during proliferative stages of mammary gland development, is found at higher levels in human breast cancers, and promotes susceptibility to mammary tumourigenesis when combined with loss of p53. We hypothesized that Spy1 cooperates with loss of p53 to increase susceptibility to tumour initiation due to changes in susceptible mammary stem cell populations during development and drives the formation of more aggressive stem like tumours.</p><p><strong>Methods: </strong>Using a transgenic mouse model driving expression of Spy1 within the mammary gland, mammary development and stemness were assessed. These mice were intercrossed with p53 null mice to study the tumourigenic properties of Spy1 driven p53 null tumours, as well as global changes in signaling via RNA sequencing analysis.</p><p><strong>Results: </strong>We show that elevated levels of Spy1 leads to expansion of mammary stem cells, even in the presence of p53, and an increase in mammary tumour formation. Spy1-driven tumours have an increased cancer stem cell population, decreased checkpoint signaling, and demonstrate an increase in therapy resistance. Loss of Spy1 decreases tumor onset and reduces the cancer stem cell population.</p><p><strong>Conclusions: </strong>This data demonstrates the potential of Spy1 to expand mammary stem cell populations and contribute to the initiation and progression of aggressive, breast cancers with increased cancer stem cell populations.</p>","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":null,"pages":null},"PeriodicalIF":7.4000,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212383/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13058-024-01862-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The cell cycle of mammary stem cells must be tightly regulated to ensure normal homeostasis of the mammary gland to prevent abnormal proliferation and susceptibility to tumorigenesis. The atypical cell cycle regulator, Spy1 can override cell cycle checkpoints, including those activated by the tumour suppressor p53 which mediates mammary stem cell homeostasis. Spy1 has also been shown to promote expansion of select stem cell populations in other developmental systems. Spy1 protein is elevated during proliferative stages of mammary gland development, is found at higher levels in human breast cancers, and promotes susceptibility to mammary tumourigenesis when combined with loss of p53. We hypothesized that Spy1 cooperates with loss of p53 to increase susceptibility to tumour initiation due to changes in susceptible mammary stem cell populations during development and drives the formation of more aggressive stem like tumours.

Methods: Using a transgenic mouse model driving expression of Spy1 within the mammary gland, mammary development and stemness were assessed. These mice were intercrossed with p53 null mice to study the tumourigenic properties of Spy1 driven p53 null tumours, as well as global changes in signaling via RNA sequencing analysis.

Results: We show that elevated levels of Spy1 leads to expansion of mammary stem cells, even in the presence of p53, and an increase in mammary tumour formation. Spy1-driven tumours have an increased cancer stem cell population, decreased checkpoint signaling, and demonstrate an increase in therapy resistance. Loss of Spy1 decreases tumor onset and reduces the cancer stem cell population.

Conclusions: This data demonstrates the potential of Spy1 to expand mammary stem cell populations and contribute to the initiation and progression of aggressive, breast cancers with increased cancer stem cell populations.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在乳腺发育和肿瘤发生过程中,非典型细胞周期调控促进了乳腺干细胞的扩增。
背景:乳腺干细胞的细胞周期必须受到严格调控,以确保乳腺的正常平衡,防止异常增殖和易发肿瘤。非典型细胞周期调节剂Spy1可覆盖细胞周期检查点,包括由肿瘤抑制因子p53激活的检查点,而p53介导乳腺干细胞的平衡。在其他发育系统中,Spy1也被证明能促进特定干细胞群的扩增。Spy1 蛋白在乳腺发育的增殖阶段会升高,在人类乳腺癌中含量较高,当与 p53 一起缺失时,会促进乳腺肿瘤发生的易感性。我们假设,Spy1与p53缺失合作,增加了肿瘤发生的易感性,这是由于在发育过程中易感的乳腺干细胞群发生了变化,并推动了更具侵袭性的干细胞样肿瘤的形成:方法:利用转基因小鼠模型驱动乳腺内Spy1的表达,对乳腺发育和干性进行评估。这些小鼠与 p53 基因无效小鼠杂交,研究 Spy1 驱动的 p53 基因无效肿瘤的致瘤特性,以及通过 RNA 测序分析了解信号传导的整体变化:结果:我们发现,即使在p53存在的情况下,Spy1水平的升高也会导致乳腺干细胞的扩增,并增加乳腺肿瘤的形成。Spy1驱动的肿瘤中癌症干细胞数量增加,检查点信号转导减少,耐药性增加。Spy1缺失会降低肿瘤发病率,减少癌干细胞数量:这些数据证明了Spy1扩大乳腺干细胞群的潜力,并有助于侵袭性乳腺癌的发生和发展,增加癌干细胞群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
12.00
自引率
0.00%
发文量
76
审稿时长
12 weeks
期刊介绍: Breast Cancer Research, an international, peer-reviewed online journal, publishes original research, reviews, editorials, and reports. It features open-access research articles of exceptional interest across all areas of biology and medicine relevant to breast cancer. This includes normal mammary gland biology, with a special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal covers preclinical, translational, and clinical studies with a biological basis, including Phase I and Phase II trials.
期刊最新文献
Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 h + HER2- breast cancer: a retrospective analysis. PTPN20 promotes metastasis through activating NF-κB signaling in triple-negative breast cancer. The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer. Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy. Breast cancer in women with previous gestational diabetes: a nationwide register-based cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1